Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 2666)

COMPLETION OF THE PUBLIC ISSUANCE OF THE CORPORATE BONDS (TRANCHE 5) IN THE PRC BY CHINA UNIVERSAL LEASING CO., LTD., A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY

This announcement is made by Genertec Universal Medical Group Company Limited (the "Company") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the announcement of the Company dated 17 December 2024 (the "Announcement") in relation to the public issuance of the fifth tranche of the corporate bonds in 2024 (the "T5 Corporate Bonds") in the People's Republic of China (the "PRC") by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) (the "Issuer"), a wholly-owned subsidiary of the Company. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to announce that the issuance of the T5 Corporate Bonds in the PRC was completed on 20 December 2024. The total principal amount of the T5 Corporate Bonds is RMB500 million, and the Bonds are with a basic term of five years from 20 December 2024, and a fixed interest rate of 2.13%. At the end of the third year of which the Issuer will be entitled to a repurchase option and a coupon rate adjustment option, while the investors will be entitled to a

sell-back option. The issue price is RMB100 per bond, which is equal to 100% of the principal value of the T5 Corporate Bonds.

Beijing, PRC,20 December 2024

As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.